|
NEOSIL
ANNOUNCES POSITIVE PHASE 2 DATA FOR NEOSH101, AN INVESTIGATIONAL TREATMENT FOR
ANDROGENETIC ALOPECIA
Emeryville, CA – January
4, 2007 – Neosil, Inc., a privately held dermatology-focused pharmaceutical
company, today announced positive Phase 2a clinical data demonstrating that its
lead product, NEOSH101, increased hair growth significantly in men diagnosed
with androgenetic alopecia, also known as pattern hair loss (PHL). Androgenetic
alopecia or PHL, caused by a combination of genetic and hormonal factors, is
noticeable in about 20 percent of the population by age 20 and increases steadily
with age. By age 50 approximately half of the U.S. population will have some
degree of PHL. “
Based on the results of this study, we are quite encouraged
by the increase in hair growth observed after such a short once-daily treatment
regimen with NEOSH101,” said Vera H. Price, MD, FRCP(C), Professor of Clinical
Dermatology, Department of Dermatology, University of California, San Francisco.
In a randomized, double-blind Phase 2a clinical study, conducted in Germany,
50 men with androgenetic alopecia (Norwood/Hamilton grades III-IV) received once-daily
topical treatments of NEOSH101 or placebo over two 14-day treatment periods,
which were separated by a one-month drug-free interval. Hair growth was measured
using an objective photographic, computer-based analysis for up to 24 weeks after
initiation of therapy. Results show that NEOSH101 was safe and well tolerated.
A statistically significant increase in total hair count (4.8%, p=0.04), and
cumulative hair thickness (3.7%, p=0.02) were observed, with peak effects occurring
eight weeks following the second treatment cycle.
“The results of this
study are encouraging, particularly the finding of increased numbers of terminal
hairs, those hairs that are thicker than 40 microns and desirable for scalp coverage,” said
Andria Langenberg, M.D., Vice President of Clinical Development at Neosil. “We
plan to initiate a Phase 2b study to evaluate daily treatment with NEOSH101 for
a longer treatment period in men with PHL.”
About Neosil
Neosil, Inc. is a privately held dermatology-focused pharmaceutical
company that was funded in November 2004 with a $32 million investment by MPM
Capital and Burrill & Company, following initial incubation funding by Shalon
Ventures, LP. In addition to its topical hair growth product, NEOSH101, Neosil
is developing a broad-spectrum topical anti-microbial agent for acne and anti-infective
use.
|
|
|
